Evidence map›Paper›PMID 33535269›Full record

ArticleNuklearmedizin. Nuclear medicine2021

Third generation radioimmunoassay (RIA) for TSH receptor autoantibodies (TRAb) - one step less, similar results?

Johannes J Roggenbuck, Grit Zarske, Peter Schierack, Gerd Wunderlich, Karsten Conrad, Joerg Kotzerke, Dirk Roggenbuck, Klaus Zöphel

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuklearmedizin. Nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Johannes J RoggenbuckDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Germany.
Grit ZarskeMedipan GmbH, Berlin/Dahlewitz, Germany.
Peter SchierackInstitute of Biotechnology, Faculty Environment and Natural Sciences, Brandenburg University of Technology, Senftenberg, Germany.
Gerd WunderlichDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Germany.
Karsten ConradInstitute of Immunology, University Hospital Carl Gustav Carus, TU Dresden, Germany.
Joerg KotzerkeDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Germany.
Dirk RoggenbuckMedipan GmbH, Berlin/Dahlewitz, Germany.
Klaus ZöphelDepartment of Nuclear Medicine, University Hospital Carl Gustav Carus, TU Dresden, Germany.
TU Dresden · DEBrandenburg University of Technology Cottbus-Senftenberg · DEMedipan (Germany) · DEUniversity Hospital Carl Gustav Carus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTSH-receptor (TSHR)-autoantibody (TRAb) is the serological hallmark of Graves' disease (GD). Recently, 3

methodsAs current assays typically employ a consecutive incubation of patient serum and labelled monoclonal TRAb, automation of TRAb RIA is a challenge. Thus, the assay procedure using human TSHR-coated tubes and the mouse monoclonal TRAb T7 was modified by combining both steps. The novel one-step method was compared with its corresponding consecutive 3

resultsWith the new method, the incubation time was shortened by approximately one hour. Both 3

conclusionOne-step 3

Indexed as

AutoantibodiesGraves DiseaseRadioimmunoassayReceptors, ThyrotropinAdultAgedFemaleHumansMaleMiddle AgedReproducibility of ResultsSensitivity and SpecificityAutoantibodiesReceptors, Thyrotropin

Identifiers

PMID33535269
PMCPMC7857932
OpenAlexW3128915685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.